It can be envisaged that NLRC5-deficient clones arising during cancer progression, lacking both MHC-Ia and MHC-Ib, would impair conventional and unconventional CD8+ T cell activation towards these clones but would favor NK cell activation. This evidence concerns the gene NLRC5 and cancer.